April 12, 2012
John McPherson presents at the IDIBAPS Seminar a pilot project to use genome sequencing in the treatment of cancer
The genome holds important information about many diseases. Next-generation sequencing is shortening the time to read all this information and making it cheaper. Moreover, today genomic research is able to provide information useful for physicians in the management of patients. Dr. John McPherson, Genome Technologies Director at Ontario Institute for Cancer Research, presented on April 10th a project focused on cancer that is already offering relevant genomic information to doctors and patients through a clinical platform. The Seminar was hosted by Dr. Elias Campo, Research Director of the Hospital Clínic of Barcelona and co-director of the Chronic Lymphocytic Leukemia (CLL) Genome Project.
New sequencing technologies have made possible the systematic identification of genetic mutations and other genomic changes in large sample sets. The Genome Technologies Platform led by Dr. John McPherson catalogues genetic alterations that occur in different types of cancers to better classify tumours and refine and develop new targeted treatments and diagnostic tools. Pancreatic ductal carcinoma and prostate cancer are major research targets.
The Genome Technologies platform is participating in a pilot project to use next-generation sequencing as a clinical tool in the treatment of cancer. During the IDIBAPS Seminar he talked about how variants in the human genome and incidental findings increase the complexity of the data. Their platform generates a digested report whit the information relevant for the clinical management of the patient. Dr. John McPherson also underlined they are working to reduce the amount of RNA/DNA needed to obtain genomic information and their strategies to increase the accuracy of the results.